

# The End Brain Cancer Initiative Announces 2025 National Patient Disease Education Initiative and HOPE Award Recipient

*The End Brain Cancer Initiative Announces 2025 National Patient Disease Education Initiative and HOPE Award Recipient*

REDMOND, WA, UNITED STATES, June 12, 2025 /EINPresswire.com/ -- FOR IMMEDIATE RELEASE

Contact: Dellann Elliott Mydland, 425-785-8489,  
Dellann@EndBrainCancer.org

The [End Brain Cancer Initiative](#) Announces 2025 National Patient Disease Education Initiative and HOPE Award Recipient

Every May for over a decade, the End Brain Cancer Initiative (EBCI) has presented the National HOPE Award to a brain cancer patient who deeply inspires us with their courage and story. EBCI established this patient disease education initiative and award to highlight ordinary people who have done exceptional things during their brain cancer journey, all while inspiring others.

The End Brain Cancer Initiative has announced Peter Mang as the 2025 National HOPE Award recipient. Peter was diagnosed with glioblastoma (GBM) in 2018 at the age of 34. Despite everything, Peter continues to have HOPE. "We just have to go with the good because there's always going to be something bad... but there's always going to be good things, and that's where I see hope," said Peter.

Peter's wife Katie Mang, who nominated him for the HOPE Award, said, "I don't know anyone who's been through so much and continues to choose to act in a manner that is not just good for himself but also everyone around him." Visit <https://endbraincancer.org/hope-award/> to learn



more about Peter's story and watch the HOPE Award presentation.

Peter and his wife started a nonprofit called "Go with the Good Foundation," which is focused on providing financial support, information, and resources so that those affected by advanced brain tumors can focus on their treatment, recovery, and quality of life. Learn more at <https://gowiththegood.org/>.

Thank you to presenting sponsor [Novocure](#) for making possible the 2025 HOPE Award, a national patient disease education initiative. Visit <https://www.novocure.com/> for further information.

#### About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Visit <https://www.novocure.com/> for further information.

#### About the End Brain Cancer Initiative

To support/donate to the End Brain Cancer Initiative's increased access and health delivery for patients, mission, services and programs, please visit [EndBrainCancer.org](https://EndBrainCancer.org)

The End Brain Cancer Initiative (EBCI) is a 501(c)3 non-profit patient advocacy organization focused on disease education, awareness, outreach, increasing patient access and improving Standard of Care. The End Brain Cancer Initiative, formerly known as the Chris Elliott Fund (CEF), is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, treatments, specialists, and clinical trial participation. We believe that IMMEDIATE ACCESS to these options provides this patient community with the best HOPE for survival and sustained quality of life. We partner with industry, patients, researchers, advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers so they can have empowered conversations with their medical teams. Learn more about the End Brain Cancer Initiative or how to sponsor this annual campaign at [EndBrainCancer.org](https://EndBrainCancer.org).



Peter and Katie Mang

Dellann Elliott Mydland, End Brain Cancer Initiative, 425-785-8489,

Dellann@EndBrainCancer.org

###

Dellann Elliott Mydland  
End Brain Cancer Initiative  
+1 4257858489

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[YouTube](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/821502377>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.